Stay updated on Dostarlimab Combo in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Dostarlimab Combo in Endometrial Cancer Clinical Trial page.

Latest updates to the Dostarlimab Combo in Endometrial Cancer Clinical Trial page
- Check5 days agoChange DetectedA new NEJM publication citation is added to the study record, listing the Dostarlimab paper's authors and DOI, and the entry shows a new revision (v3.5.5).SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe page's revision label was updated from v3.5.3 to v3.5.4, indicating a small behind-the-scenes update to the site's build or content.SummaryDifference0.0%

- Check48 days agoChange DetectedThe page’s revision/version footer has been updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check55 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check62 days agoChange DetectedRemoved the bibliographic citation for the NEJM article Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer from the Publications section.SummaryDifference0.1%

- Check84 days agoChange DetectedWebsite revision updated to v3.5.0. The previous revision v3.4.3 was removed.SummaryDifference0.0%

Stay in the know with updates to Dostarlimab Combo in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dostarlimab Combo in Endometrial Cancer Clinical Trial page.